Venture Fund Member Profile
|
 |
 |
Elm Street Ventures is a seed and early stage venture fund based in New Haven, Connecticut. Our emphasis is on the life sciences, with approximately 70% of our investments to date in companies developing laboratory tools, diagnostics, medical devices, therapeutics, and other health care related products and services. The remaining 30% of our commitments are in green technology, information technology and other industries.
We believe strongly that successful businesses address an attractive market with products or services well-protected by patents, trade secrets, or other means, an experienced management team, and one or more entrepreneurial founders passionate about building a successful business.
An important part of our efforts is focused on creating and initially operating life sciences companies founded on intellectual property developed at Yale University and other research institutions in the region (from New York City through Southern New England).
By providing management expertise and early stage capital, ESV catalyzes new company formation, working closely with scientists, engineers, and entrepreneurs to build significant tec5hnology companies from the seed and early stage.To date, Elm Street Ventures has co-founded and/or provided initial seed financing to nine of the dozen companies in our portfolio.
While we expect to be co-founders of companies in some circumstances, we are also interested in hearing from entrepreneurs, scientists, and engineers who have already formed or plan to form new ventures.
 |
Rob Bettigole
Managing Partner
Elm Street Ventures |
Rob is the founder and Managing Partner of Elm Street Ventures. Rob serves as Chairman of P2 Science and Samara Innovations, and is Chairman & CEO of Occam Sciences. He is Elm Street’s observer on the BioRelix board, and served as an observer on the boards of Affomix Corporation and Metagenomix. Mr. Bettigole’s venture capital experience was gained at Rothschild Ventures and Investor AB, where his investments included Maxim Integrated Products, Gensia Pharmaceuticals, and Microgenics Corporation. Subsequently, he helped found Surety Technologies, Inc., a spin out from Bellcore, and Alexion (NASDAQ: ALXN), with researchers from the Yale Medical School. Before founding Elm Street, Mr. Bettigole was president of a business that held patents on and marketed a product for bridge construction and rehabilitation, which he successfully developed and sold. Mr. Bettigole has a BS in Engineering and Applied Science from Yale University and an MPPM from the Yale School of Management, where he is an Entrepreneur-in-Residence. He is a Licensed Professional Engineer and holds several U.S. and foreign patents. Mr. Bettigole has served on the Operating Board of the Yale Entrepreneurial Institute since its founding in 2007.
Representative Investments
 |
Desmos, Inc. was founded in 2007 by Yale undergraduates and incubated at the Yale Entrepreneurial Institute until start-up funding was secured. The company develops and markets software that makes technology more useful for teachers and students. Desmos is building a common platform to allow educators to create lesson plans that will work across electronic whiteboards (“smartboards”), tablets (such as iPads), computers, and other devices from multiple manufacturers. The Company provides other software that runs in any browser, offering virtual whiteboard capability for remote, real time collaboration, teaching, and tutoring, and software that permits tutoring companies to manage their resources and client interactions. Desmos offers additional browser based software, such as a graphing calculator. |
 |
P2 Sciences, Inc. Specialty chemical company P2 Science is commercializing a novel class of surfactants invented at Yale. The company’s “c-glycosides” promise to bring to a range of industries more stable carbohydrate-based surfactants, derived from renewable feedstocks. These surfactants can be readily tuned to cost-effectively deliver desirable properties. Surfactants, a term derived from “ Surface Active Agents”, are the main ingredient in many soaps and detergents, including shampoos, laundry and dishwasher detergents, and industrial cleaners. But the $30 billion worldwide market for surfactants includes products used in personal care (e.g. cosmetics), mining, environmental remediation, oil field, agriculture, food, and many other industries. |
 |
BioRelix, Inc. is developing new antibiotics based on the breakthrough discovery by Ron Breaker’s lab at Yale of riboswitches, a new class of bacterial targets. As riboswitches are not present in higher animals, the team expects to be able to develop drugs highly effective against bacteria with minimal side effects in patients. |
 |
Retail Optimization, Inc is an emerging leader in space optimization software for retail stores. ROI’s products are substantially more sophisticated than other products on the market, allowing space planning of a store to be done on a whole store basis, as opposed to the category by category basis that has been the current industry standard. |
============================================
About FundingPost
For over Twelve Years FundingPost has worked with thousands
of Angel and Venture Capital Investors. We believe that it is
important to reach investors in every medium possible -
both online and offline. We have been directly responsible for
tons of success stories and Millions and Millions of dollars raised.
We look forward to introducing your company to the leading Venture and Angel Investors nationwide.
============================================
|
| Venture Fund Member Profile |
|
Bookmark to del.icio.us
Tweet this Profile
